RadNet (NASDAQ:RDNT) was upgraded by research analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Saturday.

Separately, Zacks Investment Research raised RadNet from a “hold” rating to a “buy” rating and set a $18.00 price target for the company in a research note on Wednesday, October 10th. One research analyst has rated the stock with a sell rating, three have given a buy rating and two have given a strong buy rating to the stock. RadNet has a consensus rating of “Buy” and a consensus target price of $15.50.

Shares of RDNT stock opened at $13.95 on Friday. RadNet has a 12-month low of $9.65 and a 12-month high of $16.54. The company has a market capitalization of $681.68 million, a P/E ratio of 48.10, a price-to-earnings-growth ratio of 3.35 and a beta of 1.19. The company has a debt-to-equity ratio of 4.56, a current ratio of 1.12 and a quick ratio of 1.12.

RadNet (NASDAQ:RDNT) last issued its quarterly earnings data on Friday, November 9th. The medical research company reported $0.10 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.05). RadNet had a positive return on equity of 14.62% and a negative net margin of 0.44%. The business had revenue of $242.10 million during the quarter, compared to the consensus estimate of $240.07 million. During the same period last year, the company earned $0.12 earnings per share. The business’s quarterly revenue was up 6.4% compared to the same quarter last year. Equities research analysts forecast that RadNet will post 0.25 EPS for the current fiscal year.

In other RadNet news, insider Norman R. Hames sold 5,000 shares of the stock in a transaction on Thursday, December 13th. The stock was sold at an average price of $12.68, for a total transaction of $63,400.00. Following the completion of the transaction, the insider now directly owns 569,000 shares of the company’s stock, valued at approximately $7,214,920. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Norman R. Hames sold 15,000 shares of the stock in a transaction on Monday, December 10th. The shares were sold at an average price of $12.57, for a total value of $188,550.00. Following the sale, the insider now owns 574,000 shares of the company’s stock, valued at approximately $7,215,180. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 35,000 shares of company stock valued at $407,950. 7.56% of the stock is currently owned by corporate insiders.

Large investors have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of RadNet by 157.8% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,624 shares of the medical research company’s stock valued at $37,000 after acquiring an additional 2,218 shares during the last quarter. United Services Automobile Association acquired a new stake in shares of RadNet during the 2nd quarter valued at $156,000. Virtu Financial LLC acquired a new stake in shares of RadNet during the 4th quarter valued at $115,000. RBF Capital LLC acquired a new stake in shares of RadNet during the 3rd quarter valued at $205,000. Finally, Campbell & CO Investment Adviser LLC lifted its position in shares of RadNet by 151.0% during the 3rd quarter. Campbell & CO Investment Adviser LLC now owns 28,427 shares of the medical research company’s stock valued at $428,000 after acquiring an additional 17,100 shares during the last quarter. Institutional investors own 60.57% of the company’s stock.

RadNet Company Profile

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.

Featured Article: Cost of Debt

Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.